Guerrilla RF filed pro forma condensed consolidated balance sheets as part of its application to uplist to the Nasdaq Capital Market. The financial information reflects the expected conversion of 22,000 Series A preferred shares into approximately 7.2 million common shares and the reclassification of $11.1 million in warrant liabilities to equity upon the potential listing.
Veradermics reported Q3 2026 financial results and highlighted clinical progress for its lead candidate VDPHL01, which recently achieved positive Phase 3 and Phase 2/3 results in male pattern hair loss. The company ended the quarter with $798.4 million in cash, which is expected to fund operations into 2030 through potential commercial launch.
“This has been a defining year for Veradermics as we advanced the development of VDPHL01 as a potential treatment for pattern hair loss in both men and women. In men, we reported topline results from two positive registration-directed trials, Studies ‘302’ and ‘304’, which collectively enrolled more than 1,000 male participants and demonstrated early, consistent, and robust hair growth.”
Reid Waldman, M.D., Chief Executive Officer of Veradermics
“These accomplishments bring us closer to addressing a significant unmet need in pattern hair loss for both men and women. We remain well capitalized to continue the development of VDPHL01 and advance preparations for a potential commercial launch, with the goal of establishing VDPHL01, if approved, as a foundational treatment for pattern hair loss.”
Reid Waldman, M.D., Chief Executive Officer of Veradermics
PowerCompute reported its Bitcoin mining and operating results for October 2026, mining 9.0 Bitcoin, a 20% increase year-over-year. The company increased its active hashrate to 800 PH/s by installing 900 more efficient miners on its existing 26 megawatts of power infrastructure.
Artificial Intelligence Technology Solutions Business Update
Artificial Intelligence Technology Solutions (AITX) provided a progress update on its 15-initiative product roadmap, reporting that four initiatives have been released and two are in partial release. The company is concentrating its engineering resources on its RAIA, ROAMEO, and SARA platforms to support its goal of reaching monthly operating cash breakeven by January 2027.
Cingulate Inc. provided a regulatory update on its lead ADHD asset, CTx-1301, following a previously received FDA Complete Response Letter (CRL). The company has substantially completed the required manufacturing work to address the FDA's requests and expects to resubmit its New Drug Application (NDA) between December 2026 and January 2027.
Coursera committed to a workforce reduction plan affecting approximately 10% of its global workforce to align its cost structure following its merger with Udemy. The company expects to incur $14 million to $17 million in cash expenditures for severance and benefits, primarily during Q4 2026 and the first half of 2027. This action is part of broader integration and synergy initiatives related to the Udemy combination.
Eagle Point Credit Company provided an unaudited estimate of its net asset value (NAV) per common share as of October 31, 2026. The company estimates the NAV to be between $3.73 and $3.83 per share.
City Therapeutics announced the first participant has been dosed in its Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease. The trial is a first-in-human study evaluating the safety, tolerability, and pharmacodynamics of the RNAi therapeutic candidate, with initial data expected in mid-2027.
Lipocine Inc. announced the dosing of the first participant in its BLOOM Phase 3 study of LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is expected to enroll approximately 120 participants and incorporates design improvements from a previous Phase 3 trial, with topline results expected in the second half of 2027.
Power Solutions International (PSI) entered into a multi-year amendment to its supply agreement with HD Construction Equipment (HCE) for GV22TI 22-liter natural gas engine long blocks. The agreement secures a fixed unit price and delivery schedule for 2027 and 2028, representing aggregate purchases of approximately $121.9 million. The deal includes a 10% advance payment structure and supports PSI's growth in the data center and stationary power generation markets.
Synchrony Financial disclosed its monthly charge-off and delinquency statistics for the thirteen months ended October 31, 2026. As of October 31, 2026, the company reported a 30+ day delinquency rate of 4.4% and an adjusted net charge-off rate of 4.6% on period-end loan receivables of $103.7 billion.
Cannae Holdings, Inc. released its third quarter 2026 financial results via a Letter to Shareholders and a press release. The company is currently transitioning its portfolio to focus on sports and entertainment-related assets to drive long-term shareholder value.
National Health Investors (NHI) furnished its supplemental information package for the third quarter ended September 30, 2026. The document provides operational metrics and portfolio overviews, including senior housing operating portfolio performance and lease coverage data. This filing serves as a Regulation FD disclosure of non-GAAP and operational data rather than a formal GAAP earnings release.
Larimar Therapeutics has completed its rolling Biologics License Application (BLA) submission to the FDA seeking accelerated approval for nomlabofusp in Friedreich’s ataxia. The filing also includes a preliminary cash balance of $128.7 million as of September 30, 2026, and an updated corporate presentation for investor meetings.
Artiva Biotherapeutics is implementing a wind-down of its operations, including the discontinuation of its AlloNK cell therapy candidate and a 94% reduction in workforce. The company estimates it will incur $27 million to $35 million in total charges, including up to $15 million for clinical trial close-out and up to $20 million for severance and termination costs. The workforce reduction is expected to be completed in the first quarter of 2027 as the company explores strategic alternatives.
Archer Aviation provided a Q3 2026 operational update, highlighting the receipt of a Market Survey Special Airworthiness Certificate from the FAA for its Midnight aircraft. The company is nearing the close of its acquisition of Wisk, Insitu, and SkyGrid from Boeing and has entered a strategic alliance with Formula 1 to explore eVTOL integration at Grand Prix events.
Aldeyra Therapeutics has requested that the FDA transfer the review jurisdiction of its ADX-2191 IND for primary vitreoretinal lymphoma from the Division of Ophthalmology to the Division of Hematologic Malignancies 2. In connection with this request, the company has withdrawn its previously agreed-upon Special Protocol Assessment (SPA) protocol, creating uncertainty and potential delays in the clinical development timeline for the candidate.
TMC's subsidiary received notification from NOAA regarding the expected timeline for a certification determination on its deep seabed exploration and commercial recovery application. NOAA expects to provide its final determination by mid-December 2026, which serves as an intermediate step in the regulatory review process under the Deep Seabed Hard Mineral Resources Act.
KALA BIO announced preliminary unaudited financial results for the third quarter of 2026, reporting a significantly reduced net loss of $0.8 million compared to $7.6 million in the prior year. The company ended the period with $7.0 million in cash and no debt as it continues its strategic shift toward building an AI infrastructure platform for the biotechnology industry.
Bitmine Immersion Technologies disclosed its current treasury holdings, reporting total crypto, cash, and marketable securities of $14.3 billion. The company now holds 6.07 million ETH tokens, representing 4.97% of the total ETH supply, and reaffirmed its strategy of weekly ETH accumulation.
Vistagen announced a productive Type C meeting with the FDA regarding the Phase 3 development path for its lead candidate, fasedienol, in social anxiety disorder (SAD). The FDA provided constructive feedback on using the Liebowitz Social Anxiety Scale (LSAS) as a primary endpoint and recommended incorporating interim assessments to evaluate long-term functional improvement.
OneMedNet reported year-to-date contracted bookings of $18.76 million as of November 6, 2026, representing a significant increase over 2025 levels. The company also released a growth recap titled 'OneMedNet by the Numbers' highlighting its commercial trajectory and AI-driven real-world data platform performance.
Super League Enterprise announced that between November 4 and November 9, 2026, it purchased 16 Bitcoin at an average price of approximately $76,892.32 per coin. The acquisition is part of the company's strategy to explore Bitcoin as a treasury reserve asset alongside its cash and cash equivalents.
DeFi Development Corp. announced it increased its Solana (SOL) treasury holdings by 8,881 SOL between November 2 and November 6, 2026, bringing its total holdings to approximately 2.61 million SOL. This marks the company's ninth consecutive week of SOL purchases as part of its strategy to accumulate and compound digital assets through staking and validator infrastructure.
Strive, Inc. provided an operational update disclosing the purchase of 29 additional bitcoin at an average price of $75,721 per coin between October 31 and November 6, 2026. The filing also updated the company's treasury holdings, reporting a total of 43,153 bitcoin held and $487.6 million in cash and cash equivalents as of November 6, 2026.
NovoCure received a Not Approvable Letter from the FDA regarding its Premarket Approval (PMA) application for Optune Mya for treating brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the degree of clinical benefit rather than safety concerns, and the company plans to meet with the regulator to discuss potential paths forward without additional clinical studies.
Sable Offshore Corp. reported third quarter 2026 operational results, including average daily net sales volumes of 27 thousand barrels of oil per day and a 13% increase in revenue. The company provided updates on Platform Hondo, noting that physical inspections are scheduled for November with full production expected in December 2026. Additionally, Sable diversified its marketing by adding three new Los Angeles-area refinery customers following a downstream purchaser disruption in October.
First Breach announced a strategic supply agreement to purchase up to 20 million primers per month and a separate raw material sourcing agreement to support its production ramp. The company also added two ammunition inspection units to its Hagerstown facility as it scales toward a capacity of 20 million rounds per month and transitions to 24-hour operations.
FiEE, Inc. announced the completion of its 'Harmony of Ink' international art exhibition and auction in Kyoto, Japan, which generated $2.9 million in gross transaction value. The company realized approximately $1.3 million in service revenue from the event as part of its strategy to build an 'ArtTech' O2O ecosystem. FiEE plans to expand this model through art advisory services and digital platforms targeting millennial and Gen Z collectors.
Kardigan, Inc. has completed enrollment for its Phase 2b KATALYST-AV trial evaluating ataciguat in patients with aortic stenosis. The company also updated its trial protocol to assess the primary endpoint of aortic valve calcium at week 48 instead of earlier, based on real-world data analysis of disease progression. Topline data from the trial is now expected in the second half of 2027.